Biomap, a biotechnology start-up co-established by Baidu founder Robin Li Yanhong and backed by the Hong Kong government, says it has surpassed Alphabet subsidiary AlphaFold in commercialising artificial intelligence foundation models for drug discovery. Multinational pharmaceutical companies were seeing a “reverse” in the technological gap between Biomap and AlphaFold, Wei Liu, co-founder and CEO of…
Shuimu BioSciences, a Chinese start-up specialising in advanced imaging devices for viruses and smaller biomolecules, is aiming for an initial public offering in 2027 after selling its first self-developed product this year, according to CEO Allen Guo Chunlong. The company focuses on cryo-electron microscopy (Cryo-EM), a technique that involves firing beams of electrons at flash-frozen…
Northeastern University professor Raymond Booth first learned about propranolol, a drug developed to treat high blood pressure, in pharmacy school around 1978. In graduate school, he noticed classmates using the drug not for heart conditions but to manage situational anxiety, especially during exams. Curious, he asked a friend how she knew to take it. She…
XtalPi Holdings, an artificial intelligence (AI) drug discovery firm based in the Greater Bay Area, is changing the biopharmaceutical industry by leveraging AI and robotics to transform traditional approaches to drug development. The company’s self-developed large language model (LLM), the technology underpinning ChatGPT-like generative AI services, has helped increase the success rate of chemical experiments…